Israeli-Dutch scientific stage biotech firm Prilenia Therapeutics has introduced a collaboration and licensing settlement for its lead drug Pridopidine, with Spanish pharmaceutical firm Ferrer. As a part of the settlement Prilenia will obtain €125 million in quick and near-term milestone funds and as much as €500 million total together with all milestone funds in addition to royalties if the product is improved and gross sales efficiently available on the market.
In alternate, Ferrer will obtain the rights to market the drug in Europe and different markets, whereas the US market will stay in Prilenia’s arms. This can be a comparatively excessive quantity that the corporate is receiving for an settlement that also leaves it answerable for the US market.
Pridopidine was delivered to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) by Dr. Michael Hayden, who served as Teva’s director of progressive R&D underneath CEO Dr. Jeremy Levine. With the $40 billion acquisition of Actavis and Teva’s spiralling right into a money movement disaster, the corporate determined to forgo a big a part of its growth plans, together with this drug.
Prilenia CEO Dr. Hayden bought the event rights in alternate for restricted future royalties and based Prilenia along with a staff of Teva veterans. He additionally based different firms that had been based mostly on Teva’s property or abilities (for instance, 89bio (Nasdaq: ETNB), which already has a market cap of $1.1 billion).
Pridopidine was initially supposed to deal with Huntington’s illness. Prilenia COO Limor Ben Har says, “Following the thorough work executed at Teva, it turned clear that the drug’s mechanism of motion is concerned in defending nerve cells from degeneration.” This made the drug related for extra indications in which there’s early nerve cell loss of life, comparable to ALS.
Outcomes exhibit potential
The corporate’s journey from its founding as a “spin-off” from Teva to the current day has not been with out disappointments, but it surely has benefitted from a number of essential occasions, which clarify the scale of the deal. In 2020, the corporate joined the Haley ALS Platform Trial, a large-scale trial performed by the Haley Institute for ALS Analysis, a well-funded institute led by the world’s main researchers within the area.
As a part of the progressive trial, which goals to speed up the event of ALS medication, a number of medication are being examined towards one another and towards placebo medication, with the institute itself managing and funding a big a part of the method.
RELATED ARTICLES
Prilenia Therapeutics raises $62.5m, names Michael Hayden CEO
The trial outcomes had been not too long ago acquired, exhibiting that Pridopidine, in addition to a number of different medication, didn’t meet the primary trial aims. Ben-Har explains, “The trial was comparatively brief – 24 weeks – and on the identical time the acceptance standards had been very liberal, permitting sufferers to be recruited as much as three years after the onset of the illness. This created a bias in favor of sufferers whose illness progresses slowly. The mixture of a brief trial and sufferers whose illness progresses slowly makes it very tough to show the drug’s effectiveness.
“In a retrospective evaluation we performed, we discovered that sufferers at a comparatively early stage however with quickly progressing illness did profit from the remedy.”
Regardless of not assembly the trial’s finish factors, the corporate intends to enter a Section III trial. Shifting from a Section II trial that didn’t meet its finish factors to Section III is typically attainable in uncommon and critical ailments, if the outcomes point out potential. Ben Har provides {that a} session assembly was held with the FDA earlier than the choice was made.
Within the Huntington’s area, the Section IIb trial additionally yielded blended outcomes. “A number of the sufferers had been taking antidopaminergic antipsychotics, and the analysis literature from latest years signifies that they could masks the impact of our drug – and that’s additionally what we noticed within the trial,” says Ben Har. “Your complete trial didn’t meet its main finish level, however an additional evaluation discovered a optimistic impact amongst sufferers who weren’t taking antidopaminergic medication.”
The European Medicines Company (EMA), permits uncommon ailments to use for approval underneath the Totality of Proof observe, the place even when a single trial fails, approval could be sought based mostly on the entire current info, together with retrospective analyses, explains Ben Har. Prilenia has already utilized for approval underneath this observe, and hopes to obtain a solution by the tip of the yr. A optimistic reply would enable the drug to succeed in the European market as early as subsequent yr.
Thus it’s comprehensible why the commercialization deal is targeted totally on Europe, which can grow to be the primary market through which the drug might be authorized, earlier than the US market.
Prilenia has 50 workers, 12 of whom are in Israel, and the proceeds from the commercialization settlement will enable it to broaden. In 2020, Prilenia raised $62.5 million led by the Forbion and with participation from Morningside Enterprise Investments, Sectoral Asset Administration, Talisman Capital Companions, and Genworks 2. In one other spherical of funding in 2021, buyers SV Well being and Sands Capital joined and thus far, the corporate has raised a complete of over $100 million.
Printed by Globes, Israel enterprise information – en.globes.co.il – on April 29, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
